Search

Your search keyword '"Leggett B."' showing total 484 results
Start Over Author "Leggett B."
484 results on '"Leggett B."'

3. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

van Gerven, N., van Erpecum, K., Ouden, J den, Brouwer, J., Vrolijk, J., Gevers, T.J., Drenth, J., Guichelaar, M., Bouma, G., Schreuder, T.C.M.A., van der Wouden, E.J., Baak, L.C., Stadhouders, P., Klemt-Kropp, M., Verhagen, M., Bhalla, A., Kuijvenhoven, J., Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Invernizzi, P., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Lopez, S. Ines, de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Vergani, D., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Colapietro, Francesca, Maisonneuve, Patrick, Lytvyak, Ellina, Beuers, Ulrich, Verdonk, Robert C., van der Meer, Adriaan J., van Hoek, Bart, Kuiken, Sjoerd D., Brouwer, Johannes T., Muratori, Paolo, Aghemo, Alessio, Carella, Francesco, van den Berg, Ad P., Zachou, Kalliopi, Dalekos, George N., Di Zeo-Sánchez, Daniel E., Robles, Mercedes, Andrade, Raul J., Montano-Loza, Aldo J., van den Brand, Floris F., Slooter, Charlotte D., Macedo, Guilherme, Liberal, Rodrigo, de Boer, Ynto S., and Lleo, Ana

Published
2024
Full Text
View/download PDF

4. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Almasio, P., Alvarez, F., Andrade, R., Arikan, C., Assis, D., Bardou-Jacquet, E., Biewenga, M., Cancado, E., Cazzagon, N., Chazouillères, O., Colloredo, G., Cuarterolo, M., Dalekos, G., Debray, D., Robles-Díaz, M., Drenth, J., Dyson, J., Efe, C., Engel, B., Ferri, S., Fontana, R., Gatselis, N., Gerussi, A., Halilbasic, E., Halliday, N., Heneghan, M., Hirschfield, G., van Hoek, B., Hørby Jørgensen, M., Indolfini, G., Iorio, R., Jeong, S., Jones, D., Kelly, D., Kerkar, N., Lacaille, F., Lammert, C., Leggett, B., Lenzi, M., Levy, C., Liberal, R., Lleo, A., Lohse, A., Ines Lopez, S., de Martin, E., McLin, V., Mieli-Vergani, G., Milkiewicz, P., Mohan, N., Muratori, L., Nebbia, G., van Nieuwkerk, C., Oo, Y., Ortega, A., Páres, A., Pop, T., Pratt, D., Purnak, T., Ranucci, G., Rushbrook, S., Schramm, C., Stättermayer, A., Swain, M., Tanaka, A., Taubert, R., Terrabuio, D., Terziroli, B., Trauner, M., Valentino, P., van den Brand, F., Villamil, A., Wahlin, S., Ytting, H., Zachou, K., Zeniya, M., Pape, Simon, Snijders, Romée J.A.L.M., Gevers, Tom J.G., Chazouilleres, Oliver, Dalekos, George N., Hirschfield, Gideon M., Lenzi, Marco, Trauner, Michael, Manns, Michael P., Vierling, John M., Montano-Loza, Aldo J., Lohse, Ansgar W., Schramm, Christoph, Drenth, Joost P.H., and Heneghan, Michael A.

Published
2022
Full Text
View/download PDF

5. Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C)

Author

Clark, PJ, Valery, PC, Strasser, SI, Weltman, M, Thompson, A, Levy, MT, Leggett, B, Zekry, A, Rong, J, Sinclair, M, George, J, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Cheng, W, Roberts, SK, Clark, PJ, Valery, PC, Strasser, SI, Weltman, M, Thompson, A, Levy, MT, Leggett, B, Zekry, A, Rong, J, Sinclair, M, George, J, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Cheng, W, and Roberts, SK

Abstract

INTRODUCTION: Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct-acting antiviral (DAA) therapy outcome and the clinical course of liver disease and 2-year survival for patients receiving HCV DAA therapy. METHODS: Adults (n = 2624) recruited from 26 Australian hospital liver clinics during 2016-2021 were followed up for 2 years. Risky alcohol use was defined by a combination of self-report (≥40 g/day of ethanol), physician-reported history of problematic alcohol use, and anti-craving medication prescription via population-based database linkage. We examined factors associated with advanced liver fibrosis and survival using multivariable logistic and Cox regression. RESULTS: Among 1634 patients (62.3%) with risky alcohol use, 24.6% reported consuming ≥40 g/day of alcohol, 98.3% physician-reported problematic alcohol use; only 4.1% were dispensed naltrexone/acamprosate. One hundred and forty-three patients with cirrhosis reported ≥40 g/day of alcohol, 6 (4.3%) were prescribed naltrexone/acamprosate. Risky alcohol use was associated with advanced fibrosis (adjusted-odds ratio 1.69, 95% confidence interval 1.32-2.17) and patients were over-represented for cirrhosis (45.1% vs. 25.6% in no-risky alcohol use [p < 0.001]) and hepatocellular carcinoma (5.7% vs. 2.5% [p < 0.001]). Sustained viral response (p = 0.319) and 2-year survival (adjusted-hazard ratio 1.98, 95% confidence interval 0.84-4.63) after DAA therapy were not associated with risky alcohol use. DISCUSSION AND CONCLUSIONS: Risky alcohol use in HCV patients was prevalent, but did not reduce HCV cure. Treatment for alcohol dependence was low. Risky alcohol use may be under-recognised in liver clinics. Better integration of addiction medicine into liver services and increased resourcing and addiction medicine training opportunities for hepatologists may help address this.

Published
2024

6. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Author

Hirschfield, G, Shiffman, M, Gulamhusein, A, Kowdley, K, Vierling, J, Levy, C, Kremer, A, Zigmond, E, Andreone, P, Gordon, S, Bowlus, C, Lawitz, E, Aspinall, R, Pratt, D, Raikhelson, K, Gonzalez-Huezo, M, Heneghan, M, Jeong, S, Ladron De Guevara, A, Mayo, M, Dalekos, G, Drenth, J, Janczewska, E, Leggett, B, Nevens, F, Vargas, V, Zuckerman, E, Corpechot, C, Fassio, E, Hinrichsen, H, Invernizzi, P, Trivedi, P, Forman, L, Jones, D, Ryder, S, Swain, M, Steinberg, A, Boudes, P, Choi, Y, Mcwherter, C, Adrover, R, Agrawal, S, Aigner, E, Martinez, A, Alden, A, Bellido, R, Jimenez, M, Ayoub, W, Baum, S, Ben-Ari, Z, Berenguer, M, Berg, C, Bessone, F, Bonder, A, Borg, B, Ruiz, C, Buggisch, P, Panero, J, Carey, E, Carmiel-Haggai, M, Carubbi, F, Grau, P, Ch'Ng, C, Cimpoeru, N, Omana, R, Corless, L, Costentin, C, Deschenes, M, Dorffel, Y, Dugalic, P, Farrell, G, Fernandez, J, Floreani, A, Francque, S, Freilich, B, Saldias, F, Galambos, M, Galati, J, Galli, A, Ganne-Carrie, N, Geyvandova, N, Gheorghe, L, Gilroy, R, Goel, A, Goeser, T, Greenbloom, S, Halota, W, Harrison, S, Hartleb, M, Heo, J, Hofer, H, Horvath, G, Huang, J, Huffman, J, Hunyady, B, Johnson, S, Kallis, Y, Khazanchi, A, Kim, K, Kim, S, Kim, Y, Kohli, A, Kontorinis, N, Lake, J, Lee, K, Mach, T, Manch, R, Maor-Kendler, Y, Mateescu, R, Minuk, G, Modi, A, Moehlen, M, Rodriguez, C, Cunill, R, Mouzas, I, Muir, A, Nagy, I, Ngu, J, Odin, J, Ogurtsov, P, Pabjan, P, Pagadala, M, Papp, M, Pares, A, Peskov, A, Peyton, A, Phillips, J, Porayko, M, Post, A, Pound, D, Rabinovitz, M, Rank, K, Reddy, K, Regula, J, Riley, T, Gomez, M, Safadi, R, Sheridan, D, Silva, M, Silveira, M, Sood, S, Sporea, I, Stanca, C, Stauber, R, Svorcan, P, Tak, W, Taylor, R, Thorburn, D, Tobias, H, Zekry, A, Trauner, M, Triantos, C, Veitsman, E, Thompson, A, Verhelst, X, Verna, E, Von Der Ohe, M, Weilert, F, Wiegand, J, Yimam, K, Yoon, S, Younes, Z, Zivony, A, Zuin, M, Hirschfield G. M., Shiffman M. L., Gulamhusein A., Kowdley K. V., Vierling J. M., Levy C., Kremer A. E., Zigmond E., Andreone P., Gordon S. C., Bowlus C. L., Lawitz E. J., Aspinall R. J., Pratt D. S., Raikhelson K., Gonzalez-Huezo M. S., Heneghan M. A., Jeong S. -H., Ladron De Guevara A. L., Mayo M. J., Dalekos G. N., Drenth J. P. H., Janczewska E., Leggett B. A., Nevens F., Vargas V., Zuckerman E., Corpechot C., Fassio E., Hinrichsen H., Invernizzi P., Trivedi P. J., Forman L., Jones D. E. J., Ryder S. D., Swain M. G., Steinberg A., Boudes P. F., Choi Y. -J., McWherter C. A., Adrover R., Agrawal S., Aigner E., Martinez A. A., Alden A. -M. S., Bellido R. J. A., Jimenez M. A. A., Ayoub W., Baum S. J., Ben-Ari Z., Berenguer M., Berg C., Bessone F. O., Bonder A., Borg B. B., Ruiz C. G. B., Buggisch P., Panero J. L. C., Carey E. J., Carmiel-Haggai M., Carubbi F., Grau P. C., Ch'ng C. L., Cimpoeru N. -C., Omana R. C., Corless L., Costentin C., Deschenes M., Dorffel Y., Dugalic P., Farrell G. C., Fernandez J. L., Floreani A., Francque S., Freilich B. L., Saldias F. A. F., Galambos M. R., Galati J., Galli A., Ganne-Carrie N., Geyvandova N., Gheorghe L. -S., Gilroy R., Goel A., Goeser T., Greenbloom S., Halota W., Harrison S. A., Hartleb M., Heo J., Hofer H., Horvath G., Huang J. C., Huffman J. L., Hunyady B., Johnson S., Kallis Y., Khazanchi A., Kim K. -A., Kim S. U., Kim Y. J., Kohli A., Kontorinis N., Lake J. R., Lee K. S., Mach T., Manch R., Maor-Kendler Y., Mateescu R. -B., Minuk G., Modi A. A., Moehlen M. W., Rodriguez C. M., Cunill R. M. M., Mouzas I., Muir A., Nagy I., Ngu J. H. (., Odin J., Ogurtsov P., Pabjan P., Pagadala M., Papp M., Pares A., Peskov A., Peyton A., Phillips J., Porayko M., Post A., Pound D. C., Rabinovitz M., Rank K., Reddy K. G., Regula J., Riley T., Gomez M. R., Safadi R., Sheridan D. A., Silva M. O., Silveira M. G., Sood S., Sporea I., Stanca C., Stauber R., Svorcan P., Tak W. Y., Taylor R. M., Thorburn D., Tobias H., Zekry A. T., Trauner M., Triantos C., Veitsman E., Thompson A. J. V., Verhelst X., Verna E. C., Von Der Ohe M., Weilert F., Wiegand J., Yimam K. K., Yoon S. K., Younes Z., Zivony A. S., Zuin M., Hirschfield, G, Shiffman, M, Gulamhusein, A, Kowdley, K, Vierling, J, Levy, C, Kremer, A, Zigmond, E, Andreone, P, Gordon, S, Bowlus, C, Lawitz, E, Aspinall, R, Pratt, D, Raikhelson, K, Gonzalez-Huezo, M, Heneghan, M, Jeong, S, Ladron De Guevara, A, Mayo, M, Dalekos, G, Drenth, J, Janczewska, E, Leggett, B, Nevens, F, Vargas, V, Zuckerman, E, Corpechot, C, Fassio, E, Hinrichsen, H, Invernizzi, P, Trivedi, P, Forman, L, Jones, D, Ryder, S, Swain, M, Steinberg, A, Boudes, P, Choi, Y, Mcwherter, C, Adrover, R, Agrawal, S, Aigner, E, Martinez, A, Alden, A, Bellido, R, Jimenez, M, Ayoub, W, Baum, S, Ben-Ari, Z, Berenguer, M, Berg, C, Bessone, F, Bonder, A, Borg, B, Ruiz, C, Buggisch, P, Panero, J, Carey, E, Carmiel-Haggai, M, Carubbi, F, Grau, P, Ch'Ng, C, Cimpoeru, N, Omana, R, Corless, L, Costentin, C, Deschenes, M, Dorffel, Y, Dugalic, P, Farrell, G, Fernandez, J, Floreani, A, Francque, S, Freilich, B, Saldias, F, Galambos, M, Galati, J, Galli, A, Ganne-Carrie, N, Geyvandova, N, Gheorghe, L, Gilroy, R, Goel, A, Goeser, T, Greenbloom, S, Halota, W, Harrison, S, Hartleb, M, Heo, J, Hofer, H, Horvath, G, Huang, J, Huffman, J, Hunyady, B, Johnson, S, Kallis, Y, Khazanchi, A, Kim, K, Kim, S, Kim, Y, Kohli, A, Kontorinis, N, Lake, J, Lee, K, Mach, T, Manch, R, Maor-Kendler, Y, Mateescu, R, Minuk, G, Modi, A, Moehlen, M, Rodriguez, C, Cunill, R, Mouzas, I, Muir, A, Nagy, I, Ngu, J, Odin, J, Ogurtsov, P, Pabjan, P, Pagadala, M, Papp, M, Pares, A, Peskov, A, Peyton, A, Phillips, J, Porayko, M, Post, A, Pound, D, Rabinovitz, M, Rank, K, Reddy, K, Regula, J, Riley, T, Gomez, M, Safadi, R, Sheridan, D, Silva, M, Silveira, M, Sood, S, Sporea, I, Stanca, C, Stauber, R, Svorcan, P, Tak, W, Taylor, R, Thorburn, D, Tobias, H, Zekry, A, Trauner, M, Triantos, C, Veitsman, E, Thompson, A, Verhelst, X, Verna, E, Von Der Ohe, M, Weilert, F, Wiegand, J, Yimam, K, Yoon, S, Younes, Z, Zivony, A, Zuin, M, Hirschfield G. M., Shiffman M. L., Gulamhusein A., Kowdley K. V., Vierling J. M., Levy C., Kremer A. E., Zigmond E., Andreone P., Gordon S. C., Bowlus C. L., Lawitz E. J., Aspinall R. J., Pratt D. S., Raikhelson K., Gonzalez-Huezo M. S., Heneghan M. A., Jeong S. -H., Ladron De Guevara A. L., Mayo M. J., Dalekos G. N., Drenth J. P. H., Janczewska E., Leggett B. A., Nevens F., Vargas V., Zuckerman E., Corpechot C., Fassio E., Hinrichsen H., Invernizzi P., Trivedi P. J., Forman L., Jones D. E. J., Ryder S. D., Swain M. G., Steinberg A., Boudes P. F., Choi Y. -J., McWherter C. A., Adrover R., Agrawal S., Aigner E., Martinez A. A., Alden A. -M. S., Bellido R. J. A., Jimenez M. A. A., Ayoub W., Baum S. J., Ben-Ari Z., Berenguer M., Berg C., Bessone F. O., Bonder A., Borg B. B., Ruiz C. G. B., Buggisch P., Panero J. L. C., Carey E. J., Carmiel-Haggai M., Carubbi F., Grau P. C., Ch'ng C. L., Cimpoeru N. -C., Omana R. C., Corless L., Costentin C., Deschenes M., Dorffel Y., Dugalic P., Farrell G. C., Fernandez J. L., Floreani A., Francque S., Freilich B. L., Saldias F. A. F., Galambos M. R., Galati J., Galli A., Ganne-Carrie N., Geyvandova N., Gheorghe L. -S., Gilroy R., Goel A., Goeser T., Greenbloom S., Halota W., Harrison S. A., Hartleb M., Heo J., Hofer H., Horvath G., Huang J. C., Huffman J. L., Hunyady B., Johnson S., Kallis Y., Khazanchi A., Kim K. -A., Kim S. U., Kim Y. J., Kohli A., Kontorinis N., Lake J. R., Lee K. S., Mach T., Manch R., Maor-Kendler Y., Mateescu R. -B., Minuk G., Modi A. A., Moehlen M. W., Rodriguez C. M., Cunill R. M. M., Mouzas I., Muir A., Nagy I., Ngu J. H. (., Odin J., Ogurtsov P., Pabjan P., Pagadala M., Papp M., Pares A., Peskov A., Peyton A., Phillips J., Porayko M., Post A., Pound D. C., Rabinovitz M., Rank K., Reddy K. G., Regula J., Riley T., Gomez M. R., Safadi R., Sheridan D. A., Silva M. O., Silveira M. G., Sood S., Sporea I., Stanca C., Stauber R., Svorcan P., Tak W. Y., Taylor R. M., Thorburn D., Tobias H., Zekry A. T., Trauner M., Triantos C., Veitsman E., Thompson A. J. V., Verhelst X., Verna E. C., Von Der Ohe M., Weilert F., Wiegand J., Yimam K. K., Yoon S. K., Younes Z., Zivony A. S., and Zuin M.

Published
2023

7. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

Author

Colapietro, Francesca, primary, Maisonneuve, Patrick, additional, Lytvyak, Ellina, additional, Beuers, Ulrich, additional, Verdonk, Robert C., additional, van der Meer, Adriaan J., additional, van Hoek, Bart, additional, Kuiken, Sjoerd D., additional, Brouwer, Johannes T., additional, Muratori, Paolo, additional, Aghemo, Alessio, additional, Carella, Francesco, additional, van den Berg, Ad P., additional, Zachou, Kalliopi, additional, Dalekos, George N., additional, Di Zeo-Sánchez, Daniel E., additional, Robles, Mercedes, additional, Andrade, Raul J., additional, Montano-Loza, Aldo J., additional, van den Brand, Floris F., additional, Slooter, Charlotte D., additional, Macedo, Guilherme, additional, Liberal, Rodrigo, additional, de Boer, Ynto S., additional, Lleo, Ana, additional, van Gerven, N., additional, van Erpecum, K., additional, Ouden, J den, additional, Brouwer, J., additional, Vrolijk, J., additional, Gevers, T.J., additional, Drenth, J., additional, Guichelaar, M., additional, Bouma, G., additional, Schreuder, T.C.M.A., additional, van der Wouden, E.J., additional, Baak, L.C., additional, Stadhouders, P., additional, Klemt-Kropp, M., additional, Verhagen, M., additional, Bhalla, A., additional, Kuijvenhoven, J., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Invernizzi, P., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Lopez, S. Ines, additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Vergani, D., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2023
Full Text
View/download PDF

9. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Pape S., Snijders R. J. A. L. M., Gevers T. J. G., Chazouilleres O., Dalekos G. N., Hirschfield G. M., Lenzi M., Trauner M., Manns M. P., Vierling J. M., Montano-Loza A. J., Lohse A. W., Schramm C., Drenth J. P. H., Heneghan M. A., Almasio P., Alvarez F., Andrade R., Arikan C., Assis D., Bardou-Jacquet E., Biewenga M., Cancado E., Cazzagon N., Colloredo G., Cuarterolo M., Dalekos G., Debray D., Robles-Diaz M., Drenth J., Dyson J., Efe C., Engel B., Ferri S., Fontana R., Gatselis N., Gerussi A., Halilbasic E., Halliday N., Heneghan M., Hirschfield G., van Hoek B., Horby Jorgensen M., Indolfini G., Iorio R., Jeong S., Jones D., Kelly D., Kerkar N., Lacaille F., Lammert C., Leggett B., Levy C., Liberal R., Lleo A., Lohse A., Ines Lopez S., de Martin E., McLin V., Mieli-Vergani G., Milkiewicz P., Mohan N., Muratori L., Nebbia G., van Nieuwkerk C., Oo Y., Ortega A., Pares A., Pop T., Pratt D., Purnak T., Ranucci G., Rushbrook S., Stattermayer A., Swain M., Tanaka A., Taubert R., Terrabuio D., Terziroli B., Valentino P., van den Brand F., Villamil A., Wahlin S., Ytting H., Zachou K., Zeniya M., Pape, S, Snijders, R, Gevers, T, Chazouilleres, O, Dalekos, G, Hirschfield, G, Lenzi, M, Trauner, M, Manns, M, Vierling, J, Montano-Loza, A, Lohse, A, Schramm, C, Drenth, J, Heneghan, M, Almasio, P, Alvarez, F, Andrade, R, Arikan, C, Assis, D, Bardou-Jacquet, E, Biewenga, M, Cancado, E, Cazzagon, N, Colloredo, G, Cuarterolo, M, Debray, D, Robles-Diaz, M, Dyson, J, Efe, C, Engel, B, Ferri, S, Fontana, R, Gatselis, N, Gerussi, A, Halilbasic, E, Halliday, N, van Hoek, B, Horby Jorgensen, M, Indolfini, G, Iorio, R, Jeong, S, Jones, D, Kelly, D, Kerkar, N, Lacaille, F, Lammert, C, Leggett, B, Levy, C, Liberal, R, Lleo, A, Ines Lopez, S, de Martin, E, Mclin, V, Mieli-Vergani, G, Milkiewicz, P, Mohan, N, Muratori, L, Nebbia, G, van Nieuwkerk, C, Oo, Y, Ortega, A, Pares, A, Pop, T, Pratt, D, Purnak, T, Ranucci, G, Rushbrook, S, Stattermayer, A, Swain, M, Tanaka, A, Taubert, R, Terrabuio, D, Terziroli, B, Valentino, P, van den Brand, F, Villamil, A, Wahlin, S, Ytting, H, Zachou, K, Zeniya, M, Pape S., Snijders R. J. A. L. M., Gevers T. J. G., Chazouilleres O., Dalekos G. N., Hirschfield G. M., Lenzi M., Trauner M., Manns M. P., Vierling J. M., Montano-Loza A. J., Lohse A. W., Schramm C., Drenth J. P. H., Heneghan M. A., Almasio P., Alvarez F., Andrade R., Arikan C., Assis D., Bardou-Jacquet E., Biewenga M., Cancado E., Cazzagon N., Colloredo G., Cuarterolo M., Dalekos G., Debray D., Robles-Diaz M., Drenth J., Dyson J., Efe C., Engel B., Ferri S., Fontana R., Gatselis N., Gerussi A., Halilbasic E., Halliday N., Heneghan M., Hirschfield G., van Hoek B., Horby Jorgensen M., Indolfini G., Iorio R., Jeong S., Jones D., Kelly D., Kerkar N., Lacaille F., Lammert C., Leggett B., Levy C., Liberal R., Lleo A., Lohse A., Ines Lopez S., de Martin E., McLin V., Mieli-Vergani G., Milkiewicz P., Mohan N., Muratori L., Nebbia G., van Nieuwkerk C., Oo Y., Ortega A., Pares A., Pop T., Pratt D., Purnak T., Ranucci G., Rushbrook S., Stattermayer A., Swain M., Tanaka A., Taubert R., Terrabuio D., Terziroli B., Valentino P., van den Brand F., Villamil A., Wahlin S., Ytting H., Zachou K., and Zeniya M.

Abstract

Background & Aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment. Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis. Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term ‘complete biochemical response’ defined as ‘normalization of serum transaminases and IgG below the upper limit of normal’ be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as ‘<50% decrease of serum transaminases within 4 weeks after initiation of treatment’. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for ‘any adverse event possibly related to treatment leading to potential drug discontinuation’. Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints. Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents

Published
2022

10. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.

Author

Clark, PJ, Valery, PC, Strasser, SI, Weltman, M, Thompson, AJ, Levy, M, Leggett, B, Zekry, A, Rong, J, Angus, P, George, J, Bollipo, S, McGarity, B, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Chu, G, Harding, D, Cheng, W, Farrell, G, Roberts, SK, Clark, PJ, Valery, PC, Strasser, SI, Weltman, M, Thompson, AJ, Levy, M, Leggett, B, Zekry, A, Rong, J, Angus, P, George, J, Bollipo, S, McGarity, B, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Chu, G, Harding, D, Cheng, W, Farrell, G, and Roberts, SK

Abstract

BACKGROUND AND AIMS: In 2016, direct-acting antiviral (DAA) treatment for hepatitis C (HCV) became available through Australia's universal health care system, with the aim of HCV elimination. We report real-world effectiveness of DAA HCV treatment in Australia from a clinically well-informed cohort, enriched for cirrhosis and prior HCV treatment. METHODS: 3413 patients were recruited from 26 hospital liver clinics across Australia from February 2016 to June 2020. Clinical history and sustained viral response (SVR) were obtained from medical records and data linkage to the Australian Pharmaceutical Benefits Scheme. Factors associated with SVR were assessed by multivariable logistic regression (MVR). RESULTS: At recruitment, 32.2% had cirrhosis (72.9% Child Pugh class B/C), and 19.9% were treatment experienced. Of the 2,939 with data, 93.3% confirmed SVR. 137 patients received second-line therapy. Patients with cirrhosis had lower SVR rate (88.4 vs. 95.8%; p < 0.001). On MVR, failure to achieve SVR was associated with Genotype 3 (adj-OR = 0.42, 95%CI 0.29-0.61), male gender (adj-OR = 0.49, 95%CI 0.31-0.77), fair/poor adherence (adj-OR = 0.52, 95%CI 0.28-0.94), cirrhosis (adj-OR = 0.57, 95%CI 0.36-0.88), FIB-4 > 3.25 (adj-OR = 0.52, 95%CI 0.33-0.83) and MELD score ≥ 20 (adj-OR = 0.25, 95%CI 0.08-0.80). Consistent results were seen in cirrhotic sub-analysis. CONCLUSIONS: Excellent SVR rates were achieved with DAAs in this real-world cohort of patients with chronic HCV infection. More advanced liver disease and clinician impression of poor adherence were associated with HCV treatment failure. Supports to improve liver fibrosis assessment skills for non-specialist DAA prescribers in the community and to optimize patient adherence are likely to enable more effective pursuit of HCV elimination in Australia.

Published
2023

13. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Author

Clark, PJ, Valery, PC, Ward, J, Strasser, S, Weltman, M, Thompson, A, Levy, MT, Leggett, B, Zekry, A, Rong, J, Angus, P, George, J, Bollipo, S, McGarity, B, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Chu, G, Harding, D, Cheng, W, Farrell, G, Roberts, SK, Clark, PJ, Valery, PC, Ward, J, Strasser, S, Weltman, M, Thompson, A, Levy, MT, Leggett, B, Zekry, A, Rong, J, Angus, P, George, J, Bollipo, S, McGarity, B, Sievert, W, Macquillan, G, Tse, E, Nicoll, A, Wade, A, Chu, G, Harding, D, Cheng, W, Farrell, G, and Roberts, SK

Abstract

BACKGROUND: First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. METHODS: Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. RESULTS: Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99). CONCLUSIONS: Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.

Published
2022

14. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Author

Pape, Simon, primary, Snijders, Romée J.A.L.M., additional, Gevers, Tom J.G., additional, Chazouilleres, Oliver, additional, Dalekos, George N., additional, Hirschfield, Gideon M., additional, Lenzi, Marco, additional, Trauner, Michael, additional, Manns, Michael P., additional, Vierling, John M., additional, Montano-Loza, Aldo J., additional, Lohse, Ansgar W., additional, Schramm, Christoph, additional, Drenth, Joost P.H., additional, Heneghan, Michael A., additional, Almasio, P., additional, Alvarez, F., additional, Andrade, R., additional, Arikan, C., additional, Assis, D., additional, Bardou-Jacquet, E., additional, Biewenga, M., additional, Cancado, E., additional, Cazzagon, N., additional, Chazouillères, O., additional, Colloredo, G., additional, Cuarterolo, M., additional, Dalekos, G., additional, Debray, D., additional, Robles-Díaz, M., additional, Drenth, J., additional, Dyson, J., additional, Efe, C., additional, Engel, B., additional, Ferri, S., additional, Fontana, R., additional, Gatselis, N., additional, Gerussi, A., additional, Halilbasic, E., additional, Halliday, N., additional, Heneghan, M., additional, Hirschfield, G., additional, van Hoek, B., additional, Hørby Jørgensen, M., additional, Indolfini, G., additional, Iorio, R., additional, Jeong, S., additional, Jones, D., additional, Kelly, D., additional, Kerkar, N., additional, Lacaille, F., additional, Lammert, C., additional, Leggett, B., additional, Lenzi, M., additional, Levy, C., additional, Liberal, R., additional, Lleo, A., additional, Lohse, A., additional, Ines Lopez, S., additional, de Martin, E., additional, McLin, V., additional, Mieli-Vergani, G., additional, Milkiewicz, P., additional, Mohan, N., additional, Muratori, L., additional, Nebbia, G., additional, van Nieuwkerk, C., additional, Oo, Y., additional, Ortega, A., additional, Páres, A., additional, Pop, T., additional, Pratt, D., additional, Purnak, T., additional, Ranucci, G., additional, Rushbrook, S., additional, Schramm, C., additional, Stättermayer, A., additional, Swain, M., additional, Tanaka, A., additional, Taubert, R., additional, Terrabuio, D., additional, Terziroli, B., additional, Trauner, M., additional, Valentino, P., additional, van den Brand, F., additional, Villamil, A., additional, Wahlin, S., additional, Ytting, H., additional, Zachou, K., additional, and Zeniya, M., additional

Published
2022
Full Text
View/download PDF

30. Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment

Author

Borowsky, J. (Jennifer), Haruki, K. (Koichiro), Lau, M. C. (Mai Chan), Costa, A. D. (Andressa Dias), Väyrynen, J. P. (Juha P.), Ugai, T. (Tomotaka), Arima, K. (Kota), da Silva, A. (Annacarolina), Felt, K. D. (Kristen D.), Zhao, M. (Melissa), Gurjao, C. (Carino), Twombly, T. S. (Tyler S.), Fujiyoshi, K. (Kenji), Väyrynen, S. A. (Sara A.), Hamada, T. (Tsuyoshi), Mima, K. (Kosuke), Bullman, S. (Susan), Harrison, T. A. (Tabitha A.), Phipps, A. I. (Amanda I.), Peters, U. (Ulrike), Ng, K. (Kimmie), Meyerhardt, J. A. (Jeffrey A.), Song, M. (Mingyang), Giovannucci, E. L. (Edward L.), Wu, K. (Kana), Zhang, X. (Xuehong), Freeman, G. J. (Gordon J.), Huttenhower, C. (Curtis), Garrett, W. S. (Wendy S.), Chan, A. T. (Andrew T.), Leggett, B. A. (Barbara A.), Whitehall, V. L. (Vicki L. J.), Walker, N. (Neal), Brown, I. (Ian), Bettington, M. (Mark), Nishihara, R. (Reiko), Fuchs, C. S. (Charles S.), Lennerz, J. K. (Jochen K.), Giannakis, M. (Marios), Nowak, J. A. (Jonathan A.), and Ogino, S. (Shuji)

Subjects
immunology, stomatognathic diseases, stomatognathic system, molecular pathological epidemiology, microbiome, tumor microenvironment, colorectal neoplasms
Abstract

Purpose: While evidence indicates that Fusobacterium nucleatum (F. nucleatum) may promote colorectal carcinogenesis through its suppressive effect on T-cell–mediated antitumor immunity, the specific T-cell subsets involved remain uncertain. Experimental Design: We measured F. nucleatum DNA within tumor tissue by quantitative PCR on 933 cases (including 128 F. nucleatum–positive cases) among 4,465 incident colorectal carcinoma cases in two prospective cohorts. Multiplex immunofluorescence combined with digital image analysis and machine learning algorithms for CD3, CD4, CD8, CD45RO (PTPRC isoform), and FOXP3 measured various T-cell subsets. We leveraged data on Bifidobacterium, microsatellite instability (MSI), tumor whole-exome sequencing, and M1/M2-type tumor-associated macrophages [TAM; by CD68, CD86, IRF5, MAF, and MRC1 (CD206) multimarker assay]. Using the 4,465 cancer cases and inverse probability weighting method to control for selection bias due to tissue availability, multivariable-adjusted logistic regression analysis assessed the association between F. nucleatum and T-cell subsets. Results: The amount of F. nucleatum was inversely associated with tumor stromal CD3⁺ lymphocytes [multivariable OR, 0.47; 95% confidence interval (CI), 0.28–0.79, for F. nucleatum–high vs. -negative category; Ptrend = 0.0004] and specifically stromal CD3⁺CD4⁺CD45RO⁺ cells (corresponding multivariable OR, 0.52; 95% CI, 0.32–0.85; Ptrend = 0.003). These relationships did not substantially differ by MSI status, neoantigen load, or exome-wide tumor mutational burden. F. nucleatum was not significantly associated with tumor intraepithelial T cells or with M1 or M2 TAMs. Conclusions: The amount of tissue F. nucleatum is associated with lower density of stromal memory helper T cells. Our findings provide evidence for the interactive pathogenic roles of microbiota and specific immune cells.

Published
2021

32. Globetrotting strangles: the unbridled national and international transmission of Streptococcus equi between horses

Author

Mitchell, C, Steward, KF, Charbonneau, ARL, Walsh, S, Wilson, H, Timoney, JF, Wernery, U, Joseph, M, Craig, D, van Maanen, K, Hoogkamer- van Gennep, A, Leon, A, Witkowski, L, Rzewuska, M, Stefanska, I, Zychska, M, van Loon, G, Cursons, R, Patty, O, Acke, E, Gilkerson, JR, El-Hage, C, Allen, J, Bannai, H, Kinoshita, Y, Niwa, H, Becu, T, Pringle, J, Guss, B, Bose, R, Abbott, Y, Katz, L, Leggett, B, Buckley, TC, Blum, SE, Lopez, FC, Ros, AF, Campi, MCM, Preziuso, S, Robinson, C, Newton, JR, Schofield, E, Brooke, B, Boursnell, M, de Brauwere, N, Kirton, R, Barton, CK, Abudahab, K, Taylor, B, Yeats, CA, Goater, R, Aanensen, DM, Harris, SR, Parkhill, J, Holden, MTG, Waller, AS, Mitchell, C, Steward, KF, Charbonneau, ARL, Walsh, S, Wilson, H, Timoney, JF, Wernery, U, Joseph, M, Craig, D, van Maanen, K, Hoogkamer- van Gennep, A, Leon, A, Witkowski, L, Rzewuska, M, Stefanska, I, Zychska, M, van Loon, G, Cursons, R, Patty, O, Acke, E, Gilkerson, JR, El-Hage, C, Allen, J, Bannai, H, Kinoshita, Y, Niwa, H, Becu, T, Pringle, J, Guss, B, Bose, R, Abbott, Y, Katz, L, Leggett, B, Buckley, TC, Blum, SE, Lopez, FC, Ros, AF, Campi, MCM, Preziuso, S, Robinson, C, Newton, JR, Schofield, E, Brooke, B, Boursnell, M, de Brauwere, N, Kirton, R, Barton, CK, Abudahab, K, Taylor, B, Yeats, CA, Goater, R, Aanensen, DM, Harris, SR, Parkhill, J, Holden, MTG, and Waller, AS

Abstract

The equine disease strangles, which is characterized by the formation of abscesses in the lymph nodes of the head and neck, is one of the most frequently diagnosed infectious diseases of horses around the world. The causal agent, Streptococcus equi subspecies equi, establishes a persistent infection in approximately 10 % of animals that recover from the acute disease. Such 'carrier' animals appear healthy and are rarely identified during routine veterinary examinations pre-purchase or transit, but can transmit S. equi to naïve animals initiating new episodes of disease. Here, we report the analysis and visualization of phylogenomic and epidemiological data for 670 isolates of S. equi recovered from 19 different countries using a new core-genome multilocus sequence typing (cgMLST) web bioresource. Genetic relationships among all 670 S. equi isolates were determined at high resolution, revealing national and international transmission events that drive this endemic disease in horse populations throughout the world. Our data argue for the recognition of the international importance of strangles by the Office International des Épizooties to highlight the health, welfare and economic cost of this disease. The Pathogenwatch cgMLST web bioresource described herein is available for tailored genomic analysis of populations of S. equi and its close relative S. equi subspecies zooepidemicus that are recovered from horses and other animals, including humans, throughout the world. This article contains data hosted by Microreact.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results